Nat Commun:新技术可预测血栓形成

2016-01-12 佚名 生物谷

来自哈佛大学Wyss研究所的科学家们开发了一种能够检测血栓形成风险的新技术,这对于凝血和血小板功能异常的病人来说可能是一个好消息。相关研究结果发表在国际学术期刊Nature Communication上。   研究人员利用一种生物物理学方法模拟血液在病人血管网络中可能发生的情况。这种技术目前可以用血液样本进行检测,未来或将可以整合到病人血液流过的其他体外装置为医生提供预见能力,帮助预

来自哈佛大学Wyss研究所的科学家们开发了一种能够检测血栓形成风险的新技术,这对于凝血和血小板功能异常的病人来说可能是一个好消息。相关研究结果发表在国际学术期刊Nature Communication上。

 
研究人员利用一种生物物理学方法模拟血液在病人血管网络中可能发生的情况。这种技术目前可以用血液样本进行检测,未来或将可以整合到病人血液流过的其他体外装置为医生提供预见能力,帮助预防血栓或内出血情况的发生。

在这项研究中,该研究团队开发了一种微流装置,血液流过这一装置就像流过体内的小型血管网络一样。通过自动的压力感应器和一套专门的算法,装置获取的数据能够得到实时分析,精确预测一份特定的血液样本何时会阻塞血管网络。
 
该装置的中空管道模拟了小血管变窄的病理学特征,这一病理学现象在病人体内可作为一些疾病治疗药物或方法的副作用出现,经常会引起血流动力学的改变,可能会导致严重威胁生命的血栓或内出血的发生。因此对于一些高风险病人来说,快速检测病人健康的止血能力,预防血栓形成就变得非常重要。
 
研究人员表示,利用这一微流装置模拟小血管的血流动力学结合最新的数据分析软件就能够实时快速量化病人的止血能力,预测血液样本或病人是否会形成血栓。
 
除此之外,该装置的实时监测能力几乎可以连续获取病人的血液凝集水平,相比于传统的一天一次或两次血液检测,能够大大降低抗凝治疗方法可能造成的毒性副作用。研究人员还表示,该装置能够检测一种使用传统方法很难发现的罕见出血紊乱疾病,患有该病的病人其血小板功能存在异常。
 
在该研究进行的一项大型动物实验中,研究人员直接将动物血管中的血液导入该微流装置测量一段时间内的血栓形成参数。通过这一研究,他们准确预测了血液样本形成血栓的时间,比目前临床使用的方法更快速更准确。
 
这项研究开发的这一新技术将为脑血栓等心血管疾病的预防和治疗带来重大意义。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880912, encodeId=4a9418809122f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 24 04:12:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086844, encodeId=201520868447f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jun 03 15:12:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903705, encodeId=c5ee1903e053b, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Dec 25 06:12:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56899, encodeId=bd1a5689944, content=技术决定一切, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 14:11:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56365, encodeId=e42556365ea, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Jan 12 13:01:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-24 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880912, encodeId=4a9418809122f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 24 04:12:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086844, encodeId=201520868447f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jun 03 15:12:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903705, encodeId=c5ee1903e053b, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Dec 25 06:12:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56899, encodeId=bd1a5689944, content=技术决定一切, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 14:11:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56365, encodeId=e42556365ea, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Jan 12 13:01:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-06-03 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880912, encodeId=4a9418809122f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 24 04:12:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086844, encodeId=201520868447f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jun 03 15:12:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903705, encodeId=c5ee1903e053b, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Dec 25 06:12:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56899, encodeId=bd1a5689944, content=技术决定一切, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 14:11:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56365, encodeId=e42556365ea, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Jan 12 13:01:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1880912, encodeId=4a9418809122f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 24 04:12:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086844, encodeId=201520868447f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jun 03 15:12:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903705, encodeId=c5ee1903e053b, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Dec 25 06:12:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56899, encodeId=bd1a5689944, content=技术决定一切, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 14:11:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56365, encodeId=e42556365ea, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Jan 12 13:01:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-13 Lynee劲飞扬

    技术决定一切

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1880912, encodeId=4a9418809122f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 24 04:12:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086844, encodeId=201520868447f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jun 03 15:12:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903705, encodeId=c5ee1903e053b, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Dec 25 06:12:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56899, encodeId=bd1a5689944, content=技术决定一切, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 14:11:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56365, encodeId=e42556365ea, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Jan 12 13:01:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 zhuzhuba1

    0

相关资讯

JAMA Intern Med:年轻女性罹患心脏病或中风后的下场是什么?

近年来,急性期心血管事件死亡率下降,但患者面临越来越多的疾病负担和困扰,对于那些年轻时便罹患心血管疾病的患者而言更加是难言的痛苦。但是研究人员尚未得知罹患心血管疾病的患者的长期生活质量和身体状况,特别是对于年轻的女性患者而言,研究人员获取的信息量更少。

Pediatrics:中心静脉置管并发症(系统回顾)

中心静脉置管(CVADs)失败或并发症的产生常常会导致某些医学诊疗措施的中断,以及病人的发病率、死亡率的增高。进行新的CVAD会导致患者风险的增加以及额外医疗资源的浪费。研究者对目前关于小儿科CVAD失败或不同种类CVAD相关并发症的研究进行了系统回顾。该研究的时间长度为过去的10年。研究者将CVAD失败定义为完成相关必须治疗前CVAD失去功能;将CVAD并发症定义为CVAD相关血流感染、置管部位

美国胸科医师学会发布VTE抗栓治疗指南

日前,美国胸科医师学会发布了静脉血栓栓塞(VTE)抗栓治疗的最新指南,包括对非维生素K拮抗剂类口服抗凝剂的使用指导。发表于《胸科》(Chest)杂志的建议最近更新或补充包括:对于腿部深静脉血栓形成(DVT)或肺栓塞(PE)的非肿瘤患者,指南建议前3个月及以后使用达比加群、利伐沙班、阿哌沙班或依度沙班,而不用维生素K拮抗剂。停止抗凝治疗的不明原因近端DVT或PE患者,如无阿司匹林禁忌,应接受阿司匹林

ASH 2015:癌症相关血栓形成患者使用LMWH治疗6月后,可换为华法林治疗

癌症相关血栓形成患者使用低分子肝素(LMWH)抗凝治疗6月后换成华法林继续抗凝治疗是安全的,并不会导致增加静脉血栓形成复发风险,也不会提高出血风险。建议癌症相关血栓形成患者一经诊断需使用LMWH抗凝治疗至少3-6个月,但是6个月之后抗凝治疗选用药物以及疗效并不明确。LMWH必需注射,而华法林可以口服。因此有研究者对这两种药物进行了比较。该研究纳入了1502名已经LMWH抗凝治疗6个月的患者,其中7

JAMA Neurol:治疗血栓溶解后脑出血——缩短诊断时间是关键

 使用重组血纤维蛋白溶酶原激活物(rtPA)治疗静脉血栓可以在四个半小时内改善缺血性卒中结果。但是,最为严重的并发症是有症状的脑出血(sICH),这一并发症发生率达6%。sICH尽管复发率很低,但其死亡率接近50%。目前治疗sICH主要是依据专家的建议,对于治疗的有效性的相关数据是很缺乏的。为了更好地了解血栓溶解相关的sICH的具体情况以及各种治疗方法的有效性。研究人员开展了一项多中心回

X-SIZER血栓抽吸导管在血栓病变中的应用(图)

X-SIZER血栓抽吸导管在血栓病变中的应用